ZA201701841B - Macrocyclic lrrk2 kinase inhibitors - Google Patents

Macrocyclic lrrk2 kinase inhibitors

Info

Publication number
ZA201701841B
ZA201701841B ZA2017/01841A ZA201701841A ZA201701841B ZA 201701841 B ZA201701841 B ZA 201701841B ZA 2017/01841 A ZA2017/01841 A ZA 2017/01841A ZA 201701841 A ZA201701841 A ZA 201701841A ZA 201701841 B ZA201701841 B ZA 201701841B
Authority
ZA
South Africa
Prior art keywords
kinase inhibitors
lrrk2 kinase
macrocyclic
macrocyclic lrrk2
inhibitors
Prior art date
Application number
ZA2017/01841A
Other languages
English (en)
Inventor
Jan Hoflack
Petra Blom
Olivier Lavergne
Sylvie Gomez
Original Assignee
Oncodesign Sa
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncodesign Sa, Ipsen Pharma Sas filed Critical Oncodesign Sa
Publication of ZA201701841B publication Critical patent/ZA201701841B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA2017/01841A 2014-09-17 2017-03-15 Macrocyclic lrrk2 kinase inhibitors ZA201701841B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14290279 2014-09-17
PCT/EP2015/071349 WO2016042089A1 (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors

Publications (1)

Publication Number Publication Date
ZA201701841B true ZA201701841B (en) 2019-08-28

Family

ID=51752058

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/01841A ZA201701841B (en) 2014-09-17 2017-03-15 Macrocyclic lrrk2 kinase inhibitors

Country Status (20)

Country Link
US (1) US10377772B2 (enExample)
EP (1) EP3194405B1 (enExample)
JP (1) JP2017529365A (enExample)
KR (1) KR20170048599A (enExample)
CN (1) CN107108641A (enExample)
AU (1) AU2015316801B2 (enExample)
BR (1) BR112017005299A2 (enExample)
CA (1) CA2960777A1 (enExample)
DK (1) DK3194405T3 (enExample)
EA (1) EA032838B1 (enExample)
ES (1) ES2717510T3 (enExample)
HU (1) HUE043972T2 (enExample)
IL (1) IL251054B (enExample)
MX (1) MX2017003470A (enExample)
PL (1) PL3194405T4 (enExample)
SG (1) SG11201701936WA (enExample)
TR (1) TR201904514T4 (enExample)
TW (1) TW201625639A (enExample)
WO (1) WO2016042089A1 (enExample)
ZA (1) ZA201701841B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111221514B (zh) * 2020-01-13 2023-03-03 陕西心像信息科技有限公司 基于OsgEarth的三维可视化组件实现方法及系统
AR124556A1 (es) * 2020-01-31 2023-04-12 Oncodesign Sa Inhibidores macrocíclicos de rip2-cinasa
UA129504C2 (uk) 2020-05-06 2025-05-14 Ле Лаборатуар Сервьє Нові макроциклічні інгібітори lrrk2-кінази
TW202304935A (zh) 2021-03-18 2023-02-01 法商施維雅藥廠 新穎的巨環lrrk2激酶抑制劑
WO2023064768A1 (en) * 2021-10-11 2023-04-20 Baylor College Of Medicine G-protein-coupled receptor regulators and methods of use thereof
WO2023073013A1 (en) * 2021-10-27 2023-05-04 H. Lundbeck A/S Lrrk2 inhibitors
CN117425660A (zh) * 2022-05-18 2024-01-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其中间体、药物组合物和用途
TW202412777A (zh) 2022-09-15 2024-04-01 丹麥商H 朗德貝克公司 富白胺酸重複激酶2(lrrk2)抑制劑
WO2024218285A1 (en) * 2023-04-20 2024-10-24 H. Lundbeck A/S Leucine-rich repeat kinase 2 (lrrk2) inhibitors
AR132488A1 (es) * 2023-04-20 2025-07-02 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
AR132487A1 (es) * 2023-04-20 2025-07-02 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
WO2024218296A1 (en) * 2023-04-20 2024-10-24 H. Lundbeck A/S Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
SK283569B6 (sk) 1993-10-01 2003-09-11 Astra Aktiebolag Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
EP0915880B1 (en) 1996-07-24 2007-10-10 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
PT1354884E (pt) 2000-12-28 2007-12-24 Ono Pharmaceutical Co Composto de ciclopenta (d) pirazolo [1,5-a] piramida como antagonista de receptor de crf
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
WO2006045392A2 (en) 2004-10-21 2006-05-04 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
FI123725B (fi) 2005-08-01 2013-10-15 Reijo Viljanen Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet
PH12012501003B1 (en) 2005-11-16 2018-04-06 Cti Biopharma Corp Oxygen linked pyrimidine derivatives
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
BR112012006859A2 (pt) 2009-09-29 2019-09-24 Glaxo Group Ltd compostos
AU2011256380C1 (en) * 2010-05-20 2016-09-08 Array Biopharma Inc. Macrocyclic compounds as Trk kinase inhibitors
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
ES2583477T3 (es) * 2011-09-30 2016-09-21 Ipsen Pharma S.A.S. Inhibidores macrocíclicos de cinasa de LRRK2
KR20140078710A (ko) * 2011-09-30 2014-06-25 온코디자인 에스.에이. 거대고리 flt3 키나제 억제제

Also Published As

Publication number Publication date
EP3194405B1 (en) 2018-12-26
WO2016042089A1 (en) 2016-03-24
KR20170048599A (ko) 2017-05-08
JP2017529365A (ja) 2017-10-05
TW201625639A (zh) 2016-07-16
PL3194405T3 (pl) 2019-07-31
EA201790626A1 (ru) 2017-07-31
US10377772B2 (en) 2019-08-13
US20170240565A1 (en) 2017-08-24
TR201904514T4 (tr) 2019-04-22
PL3194405T4 (pl) 2019-07-31
SG11201701936WA (en) 2017-04-27
CA2960777A1 (en) 2016-03-24
IL251054A0 (en) 2017-04-30
AU2015316801B2 (en) 2019-03-07
AU2015316801A1 (en) 2017-04-27
HUE043972T2 (hu) 2019-09-30
BR112017005299A2 (pt) 2017-12-12
MX2017003470A (es) 2017-08-07
ES2717510T3 (es) 2019-06-21
CN107108641A (zh) 2017-08-29
DK3194405T3 (en) 2019-04-15
IL251054B (en) 2019-03-31
EP3194405A1 (en) 2017-07-26
EA032838B1 (ru) 2019-07-31

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
ZA201901034B (en) Macrocycle kinase inhibitors
EP3172213A4 (en) Macrocyclic kinase inhibitors and uses thereof
IL248086B (en) Biaryl kinase inhibitors
EP3131900A4 (en) Heterocyclic kinase inhibitors
ZA201701841B (en) Macrocyclic lrrk2 kinase inhibitors
IL251784A0 (en) Bromodomain inhibitors
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
GB201615282D0 (en) Tankyrase inhibitors
ZA201506327B (en) Macrocyclic lrrk2 kinase inhibitors
SG11201609350XA (en) Methods for inhibiting necroptosis
IL258438B (en) 2-Aminoquinoline derivatives as p70s6 kinase inhibitors
ZA201701331B (en) Macrocyclic rip2 kinase inhibitors
EP3201181A4 (en) Sphingosine kinase inhibitors
GB201414116D0 (en) Benzodiazepine derivatives
GB201404555D0 (en) Macrocyclic kinase inhibitors
GB201404570D0 (en) Macrocyclic kinase inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201519381D0 (en) Kinase inhibitors
GB201614783D0 (en) Kinases inhibitors
AU2014903812A0 (en) Novel kinase inhibitors i
GB201418154D0 (en) Inhibitors
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors